Condition
Group B Streptococcus Carrier in Childbirth
Total Trials
5
Recruiting
0
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 3 (1)
Trial Status
Unknown3
Active Not Recruiting2
Clinical Trials (5)
Showing 5 of 5 trials
NCT04549220Active Not RecruitingPrimary
Serosurveillance Study of Maternally Derived Anti-GBS Antibody
NCT03696953Phase 2Active Not RecruitingPrimary
The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization.
NCT04653948UnknownPrimary
Maternal, Neonatal and Infant Outcomes at Kawempe National Referral Hospital
NCT04732026UnknownPrimary
Serocorrelate of Protection Against GBS (PREPARE WP3)
NCT03407157Phase 3UnknownPrimary
Oral Probiotic Supplementation in Pregnancy to Reduce Group B Streptococcus Colonization
Showing all 5 trials